Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05720663 · ClinicalTrials.gov registry record
Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
A clinical trial of Nonalcoholic Steatohepatitis, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- 240
- Enrollment target
- 2
- Study locations
NCT05720663: Recruiting study of Nonalcoholic Steatohepatitis, sponsored by Virginia Commonwealth University.
NCT05720663 is a study of Nonalcoholic Steatohepatitis that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 240 participants, below the 695-participant average among 30 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (65% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05720663, a study of Nonalcoholic Steatohepatitis, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- 240 participants
- Enrollment target
- 2
- Study locations
Study Summary
Nonalcoholic Steatohepatitis (NASH) is a condition with increased amount of fat, inflammation and scarring in the liver. In compensated cirrhosis, the liver is coping with this damage and maintaining its important functions. Decompensation occurs when the liver becomes unable to perform all of its functions adequately. Variceal hemorrhage (bleeding from abnormal vessels in the liver called varices), Ascites (abnormal build-up of fluid in the abdomen), and Encephalopathy (brain confusion as a result of the liver not being able to get rid of toxic substances) are three symptoms of liver decompensation. The purpose of this research study is to investigate better ways to routinely monitor the condition of patients with NASH with compensated cirrhosis and to better pinpoint the development of decompensation in the livers of these patients.
Primary Outcome
Number of deaths will be determined from death records and patient charts.
Conditions Studied
Interventions
- OTHER Standard of care
Study Locations (2)
Minnesota
- Mayo Clinic in Rochester - Rochester
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2023-04-19 |
| Est. Completion | 2027-12 |
What NCT05720663 shows while recruiting
NCT05720663 is an observational study that tracks outcomes without assigning an intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 695-participant average among 30 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 1 intervention - of which Standard of care is the first listed.
NCT05720663 reports a single indexed study location in Minnesota, Virginia.
Frequently Asked Questions
What is clinical trial NCT05720663 about?
NCT05720663 is a clinical study titled "Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis". Nonalcoholic Steatohepatitis (NASH) is a condition with increased amount of fat, inflammation and scarring in the liver. In compensated cirrhosis, the liver is coping with this damage and maintaining its important functions. Decompensation occurs when the liver becomes unable to perform all of its f...
What is the current status of trial NCT05720663?
This trial is currently recruiting. The enrollment target is 240 participants. The study started on 2023-04-19. Estimated completion is 2027-12.
What conditions does trial NCT05720663 study?
This clinical trial studies the following conditions: Nonalcoholic Steatohepatitis.
What interventions are being tested in trial NCT05720663?
The interventions under investigation include: Standard of care (OTHER).
Who is sponsoring clinical trial NCT05720663?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05720663 being conducted?
This trial has 2 study locations across Minnesota, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05720663's enrollment target sits among peer trials
240 9th of 30 higher than 22 of 30 other Nonalcoholic Steatohepatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nonalcoholic Steatohepatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
RECRUITING · Phase 2
-
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
RECRUITING
-
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
RECRUITING · Phase 2
-
Metabolic Pathology of Pediatric NAFLD
RECRUITING · NA
-
Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI